Bibliographic Details
| Title: |
Development and optimization of a doxorubicin loaded poly(lactic acid) contrast agent for ultrasound directed drug delivery |
| Authors: |
Eisenbrey, J.R.1 jeisenbrey@gmail.com, Burstein, O. Mualem1 odelmb@gmail.com, Kambhampati, R.1 rekhakamb@gmail.com, Forsberg, F.2 flemming.forsberg@jefferson.edu, Liu, J.-B.2 ji-bin.liu@jefferson.edu, Wheatley, M.A.1 wheatley@coe.drexel.edu |
| Source: |
Journal of Controlled Release. Apr2010, Vol. 143 Issue 1, p38-44. 7p. |
| Subjects: |
Drug development, Mathematical optimization, Doxorubicin, Lactic acid, Intravenous therapy, Ultrasound contrast media, Drug delivery systems |
| Geographic Terms: |
New Zealand |
| Abstract: |
Abstract: An echogenic, intravenous drug delivery platform is proposed in which an encapsulated chemotherapeutic can travel to a desired location and drug delivery can be triggered using external, focused ultrasound at the area of interest. Three methods of loading poly(lactic acid) (PLA) shelled ultrasound contrast agents (UCA) with doxorubicin are presented. Effects on encapsulation efficiency, in vitro enhancement, stability, particle size, morphology and release during UCA rupture are compared by loading method and drug concentration. An agent containing doxorubicin within the shell was selected as an ideal candidate for future hepatocellular carcinoma studies. The agent achieved a maximal drug load of 6.2mg Dox/g PLA with an encapsulation efficiency of 20.5%, showed a smooth surface morphology and tight size distribution (poly dispersity index=0.309) with a peak size of 1865nm. Acoustically, the agent provided 19dB of enhancement in vitro at a dosage of 10µg/ml, with a half life of over 15min. In vivo, the agent provided ultrasound enhancement of 13.4±1.6dB within the ascending aorta of New Zealand rabbits at a dose of 0.15ml/kg. While the drug-incorporated agent is thought to be well suited for future drug delivery experiments, this study has shown that agent properties can be tailored for specific applications based on choice of drug loading method. [Copyright &y& Elsevier] |
|
Copyright of Journal of Controlled Release is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Engineering Source |
